Compared with PI3K inhibitors, NF-κB pathway inhibitors have been widely used in MM, such as bortezomib (BTZ), which induces apoptosis by inhibiting the degradation of IκBα and inhibiting the activation of NF-κB in cancer cells (Murray and Norbury, 2000). The gene discussed is NFKB1; the disease is Miyoshi myopathy.